• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Smackover Lithium's South West Arkansas Project Receives Special Designation as a Priority Transparency Critical Mineral Project From the Trump Administration

    4/21/25 6:15:51 PM ET
    $A
    $SLI
    Biotechnology: Laboratory Analytical Instruments
    Industrials
    Major Chemicals
    Industrials
    Get the next $A alert in real time by email

    LEWISVILLE, Ark., April 21, 2025 (GLOBE NEWSWIRE) -- Smackover Lithium, a Joint Venture ("JV") between Standard Lithium Ltd. ("Standard Lithium" or the "Company") (TSXV:SLI) (NYSE:A) and Equinor, is proud to announce that its South West Arkansas ("SWA") Project has been selected as one of the first critical mineral production projects to be advanced under Executive Order 14241, Immediate Measures to Increase American Mineral Production, issued on March 20, 2025, by President Trump. This prestigious designation, announced by the Federal Permitting Improvement Steering Council at the recommendation of the National Energy Dominance Council, underscores the project's strategic importance to national security, economic prosperity, and energy independence.

    The SWA Project, a cornerstone of Smackover Lithium's mission to bolster domestic lithium production, has been included on the Federal Permitting Dashboard as a transparency project. This designation ensures increased transparency, accountability, and predictability in the permitting review process, aligning with President Trump's directive to expedite domestic critical mineral projects. The support from the White House signals strong federal backing for the project, reinforcing its role in reducing U.S. reliance on China. The SWA Project is one of only three domestic lithium projects and the sole Direct Lithium Extraction ("DLE") initiative to be included on the initial selected projects list. Additionally, it is the first project supported by the DOE's Office of Manufacturing and Energy Supply Chains to be accepted into the Transparency Program.

    "We are honored by the Trump Administration's recognition of the SWA Project as a priority project for American mineral production," said Standard Lithium's CEO, David Park. "This designation is a testament to the project's economic viability and potential to strengthen national security, create high-quality jobs, and fuel economic growth in Arkansas and beyond. The streamlined permitting process, combined with federal support, reinforces our project development timeline and positions us well to deliver a low cost, sustainable, and domestic source of lithium critical to advanced energy technologies."

    Smackover Lithium remains committed to environmentally responsible development, community engagement, and innovation as it advances the SWA Project. The JV looks forward to collaborating with federal, state, and local stakeholders to ensure the project's success and to contribute to America's leadership in the critical minerals sector.

    For more information about the SWA Project and Smackover Lithium, please visit www.smackoverlithium.com.

    About Standard Lithium Ltd.

    Standard Lithium is a leading near-commercial lithium development company focused on the sustainable development of a portfolio of large, high-grade lithium-brine properties in the United States. The Company prioritizes projects characterized by the highest quality resources, robust infrastructure, skilled labor, and streamlined permitting. Standard Lithium aims to achieve sustainable, commercial-scale lithium production via the application of a scalable and fully integrated Direct Lithium Extraction ("DLE") and purification process. The Company's flagship projects are located in the Smackover Formation, a world-class lithium brine asset, focused in Arkansas and Texas. In partnership with global energy leader Equinor, Standard Lithium is advancing the South West Arkansas project, a greenfield project located in southern Arkansas, and actively exploring promising lithium brine prospects in East Texas. Standard Lithium also holds an interest in certain mineral leases in the Mojave Desert in San Bernardino County, California.

    Standard Lithium trades on both the TSX Venture Exchange and the NYSE American under the symbol "SLI". Please visit the Company's website at www.standardlithium.com.

    About Equinor

    Equinor is an international energy company committed to long-term value creation in a low-carbon future. Equinor's portfolio of projects encompasses oil and gas, renewables and low-carbon solutions, with an ambition of becoming a net-zero energy company by 2050. Headquartered in Norway, Equinor is the leading operator on the Norwegian continental shelf and is present in around 30 countries worldwide. Our partnership with Standard Lithium to mature DLE projects builds on our broad US energy portfolio of oil and gas, offshore wind, low carbon solutions and battery storage projects.

    For more information on Equinor in the US, please visit: Equinor in the US - Equinor

    Investor and Media Inquiries

    Chris Lang

    Standard Lithium Ltd.

    +1 604 409 8154

    [email protected]

    Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release. This news release may contain certain "Forward-Looking Statements" within the meaning of the United States Private Securities Litigation Reform Act of 1995 and applicable Canadian securities laws. When used in this news release, the words "anticipate", "believe", "estimate", "expect", "target", "plan", "forecast", "may", "schedule" and other similar words or expressions identify forward-looking statements or information. These forward-looking statements or information may relate to intended development timelines, future prices of commodities, accuracy of mineral or resource exploration activity, reserves or resources, regulatory or government requirements or approvals, the reliability of third party information, continued access to mineral properties or infrastructure, fluctuations in the market for lithium and its derivatives, changes in exploration costs and government regulation in Canada and the United States, and other factors or information. Such statements represent the Company's current views with respect to future events and are necessarily based upon a number of assumptions and estimates that, while considered reasonable by the Company, are inherently subject to significant business, economic, competitive, political and social risks, contingencies and uncertainties. Many factors, both known and unknown, could cause results, performance or achievements to be materially different from the results, performance or achievements that are or may be expressed or implied by such forward-looking statements. The Company does not intend, and does not assume any obligation, to update these forward-looking statements or information to reflect changes in assumptions or changes in circumstances or any other events affecting such statements and information other than as required by applicable laws, rules and regulations.



    Get the next $A alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $A
    $SLI

    CompanyDatePrice TargetRatingAnalyst
    Agilent Technologies Inc.
    $A
    1/20/2026$180.00Buy
    HSBC Securities
    Agilent Technologies Inc.
    $A
    1/5/2026$160.00In-line → Outperform
    Evercore ISI
    Agilent Technologies Inc.
    $A
    12/15/2025$165.00Equal Weight → Overweight
    Barclays
    Agilent Technologies Inc.
    $A
    12/9/2025$170.00Buy
    Goldman
    Agilent Technologies Inc.
    $A
    12/2/2025$270.00Overweight
    Morgan Stanley
    Agilent Technologies Inc.
    $A
    10/8/2025$165.00Buy
    Rothschild & Co Redburn
    Agilent Technologies Inc.
    $A
    10/8/2025$170.00Neutral → Buy
    UBS
    Standard Lithium Ltd.
    $SLI
    7/11/2025$2.75Outperform
    Raymond James
    More analyst ratings

    $A
    $SLI
    SEC Filings

    View All

    SEC Form SCHEDULE 13G filed by Standard Lithium Ltd.

    SCHEDULE 13G - STANDARD LITHIUM LTD. (0001537137) (Subject)

    2/13/26 9:29:46 AM ET
    $SLI
    Major Chemicals
    Industrials

    SEC Form DEFA14A filed by Agilent Technologies Inc.

    DEFA14A - AGILENT TECHNOLOGIES, INC. (0001090872) (Filer)

    2/6/26 7:10:03 AM ET
    $A
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    SEC Form DEF 14A filed by Agilent Technologies Inc.

    DEF 14A - AGILENT TECHNOLOGIES, INC. (0001090872) (Filer)

    2/6/26 7:00:39 AM ET
    $A
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $A
    $SLI
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    HSBC Securities initiated coverage on Agilent with a new price target

    HSBC Securities initiated coverage of Agilent with a rating of Buy and set a new price target of $180.00

    1/20/26 9:22:21 AM ET
    $A
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Agilent upgraded by Evercore ISI with a new price target

    Evercore ISI upgraded Agilent from In-line to Outperform and set a new price target of $160.00

    1/5/26 8:23:48 AM ET
    $A
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Agilent upgraded by Barclays with a new price target

    Barclays upgraded Agilent from Equal Weight to Overweight and set a new price target of $165.00

    12/15/25 8:55:45 AM ET
    $A
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $A
    $SLI
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Agilent to Participate in TD Cowen's 46th Annual Health Care Conference

    Agilent Technologies Inc. (NYSE:A) today announced that Chief Financial Officer Adam Elinoff and Head of Investor Relations Tejas Savant will participate in a fireside chat at TD Cowen's 46th Annual Health Care Conference. The event is scheduled for 11:10 to 11:40 a.m. EST on Tuesday, March 3, 2026, in Boston, Massachusetts. A live audio webcast and replay of the presentation will be available through Agilent's Investor Relations website. About Agilent Technologies Agilent Technologies, Inc. (NYSE:A) is a global leader in analytical and clinical laboratory technologies, delivering insights and innovation that help our customers bring great science to life. Agilent's full range of soluti

    2/23/26 4:15:00 PM ET
    $A
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Agilent Announces Cash Dividend of 25.5 Cents per Share

    Agilent Technologies Inc. (NYSE:A) today announced a quarterly dividend of 25.5 cents per share of common stock. The quarterly dividend will be paid on April 22, 2026, to all shareholders of record as of the close of business on March 31, 2026. The timing and amounts of future dividends are subject to the determination and approval of Agilent's board of directors. About Agilent Technologies Agilent Technologies, Inc. (NYSE:A) is a global leader in analytical and clinical laboratory technologies, delivering insights and innovation that help our customers bring great science to life. Agilent's full range of solutions includes instruments, software, services, and expertise that provide t

    2/11/26 4:15:00 PM ET
    $A
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Agilent Presents Boehringer Ingelheim With Inaugural 2025 Instrument Trade‑In Impact Award

    Award honors leadership in sustainable laboratory practices and circular economy advancement Agilent Technologies Inc. (NYSE:A) today announced that Boehringer Ingelheim has been selected as the winner of Agilent's inaugural Instrument Trade‑In Impact Award, recognizing exceptional sustainability leadership demonstrated through their participation in Agilent's trade‑in and buyback program. The annual award honors the global partner that achieves the highest sustainability impact by diverting end‑of‑life laboratory instruments from landfill and contributing to the circular use of scientific equipment. In 2025, Boehringer Ingelheim led all partners in responsible trade‑in activity, ensuri

    2/11/26 8:00:00 AM ET
    $A
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $A
    $SLI
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Amendment: SEC Form 4 filed by V.P., Corporate Controller Gonsalves Rodney

    4/A - AGILENT TECHNOLOGIES, INC. (0001090872) (Issuer)

    1/8/26 4:05:46 PM ET
    $A
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Director Dolsten Mikael sold $389,511 worth of shares (2,600 units at $149.81), decreasing direct ownership by 34% to 4,973 units (SEC Form 4)

    4 - AGILENT TECHNOLOGIES, INC. (0001090872) (Issuer)

    12/3/25 4:04:44 PM ET
    $A
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Senior Vice President Zhang Jianmiao Mike covered exercise/tax liability with 208 shares, decreasing direct ownership by 2% to 11,639 units (SEC Form 4)

    4 - AGILENT TECHNOLOGIES, INC. (0001090872) (Issuer)

    12/1/25 4:36:53 PM ET
    $A
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $A
    $SLI
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Gonsalves Rodney (Amendment)

    4/A - AGILENT TECHNOLOGIES, INC. (0001090872) (Issuer)

    10/20/23 1:07:25 PM ET
    $A
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Gonsalves Rodney bought $288 worth of shares (3 units at $111.09), increasing direct ownership by 0.01% to 24,222 units (SEC Form 4)

    4 - AGILENT TECHNOLOGIES, INC. (0001090872) (Issuer)

    9/29/23 4:03:46 PM ET
    $A
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $A
    $SLI
    Financials

    Live finance-specific insights

    View All

    Agilent Announces Cash Dividend of 25.5 Cents per Share

    Agilent Technologies Inc. (NYSE:A) today announced a quarterly dividend of 25.5 cents per share of common stock. The quarterly dividend will be paid on April 22, 2026, to all shareholders of record as of the close of business on March 31, 2026. The timing and amounts of future dividends are subject to the determination and approval of Agilent's board of directors. About Agilent Technologies Agilent Technologies, Inc. (NYSE:A) is a global leader in analytical and clinical laboratory technologies, delivering insights and innovation that help our customers bring great science to life. Agilent's full range of solutions includes instruments, software, services, and expertise that provide t

    2/11/26 4:15:00 PM ET
    $A
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Agilent to Announce First-Quarter Fiscal Year 2026 Financial Results on Feb. 25

    Agilent Technologies Inc. (NYSE:A) will release financial results for the first quarter of fiscal year 2026 after the stock market closes on Wednesday, Feb. 25. The company will host a conference call to discuss the results at 1:30 p.m. PST the same day. To join the listen-only conference call webcast, click the link on the Events section of Agilent's Investor Relations website. A recording of the call also will be available on the website for 90 days. About Agilent Technologies Agilent Technologies, Inc. (NYSE:A) is a global leader in analytical and clinical laboratory technologies, delivering insights and innovation that help our customers bring great science to life. Agilent's full

    2/2/26 4:15:00 PM ET
    $A
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Agilent Reports Fourth-Quarter Fiscal Year 2025 Financial Results

    Delivers solid results in Q4, initiates FY26 guidance Fourth-quarter fiscal year 2025 Revenue of $1.86 billion for the fourth quarter ended October 31, 2025, exceeding revenue guidance and representing growth of 9.4% reported and up 7.2% on a core(1) basis compared with the fourth quarter of 2024. GAAP net income of $434 million; earnings per share (EPS) of $1.53, up 25% from the fourth quarter of 2024. Non-GAAP(2) net income of $452 million; EPS of $1.59, up 9% from the fourth quarter of 2024. Full fiscal year 2025 Revenue of $6.95 billion for the fiscal year ended October 31, 2025, exceeding revenue guidance and representing growth of 6.7% on a reported basis and up 4.9% on a c

    11/24/25 4:10:00 PM ET
    $A
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $A
    $SLI
    Leadership Updates

    Live Leadership Updates

    View All

    Agilent Names Adam S. Elinoff as Chief Financial Officer

    Agilent Technologies Inc. (NYSE:A) today announced the appointment of Adam S. Elinoff as chief financial officer, effective Nov. 17. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251027719923/en/Adam S. Elinoff, Chief Financial Officer, Agilent Technologies Elinoff brings two decades of financial experience spanning corporate finance, investor relations, strategy and business transformation, and has a proven record of driving enterprise-wide transformations, optimizing financial operations and scaling global capabilities. He joins Agilent from Amgen, a worldwide pioneer in biotechnology, where he advanced through a series of

    10/27/25 4:15:00 PM ET
    $A
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Standard Lithium Expands Leadership Team with Appointment of General Counsel

    VANCOUVER, British Columbia, Aug. 18, 2025 (GLOBE NEWSWIRE) -- Standard Lithium Ltd. ("Standard Lithium" or the "Company") (TSXV:SLI) (NYSE:SLI), a leading near-commercial lithium company, is announcing the appointment of Michael Lutgring as General Counsel, effective August 18, 2025. "We are excited to have Michael join our senior leadership team," said David Park, Chief Executive Officer and Director of Standard Lithium. "Michael's deep and wide-ranging experience will be critical as we strengthen our capabilities and bring further expertise in-house as we continue our growth and development as a public company." Mr. Lutgring brings over two decades of legal and strategic a

    8/18/25 8:30:00 AM ET
    $SLI
    Major Chemicals
    Industrials

    Standard Lithium Announces New VP Appointments to Expand and Strengthen Senior Management

    VANCOUVER, British Columbia, June 23, 2025 (GLOBE NEWSWIRE) -- Standard Lithium Ltd. ("Standard Lithium" or the "Company") (TSXV:SLI) (NYSE:SLI), a leading near-commercial lithium company, is pleased to announce the appointment of Daniel Rosen as Vice President of Strategy and Investor Relations, as well as Tim Sobel as Vice President of Health, Safety, Social and Environment ("HSSE"). "We are thrilled to welcome the additions of Daniel and Tim to our leadership team," said David Park, Chief Executive Officer and Director of Standard Lithium. "Dan's strategic insight and deep experience in investor relations and capital markets, as well as Tim's extensive history in ensuring that HSSE sta

    6/23/25 8:30:00 AM ET
    $SLI
    Major Chemicals
    Industrials

    $A
    $SLI
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Agilent Technologies Inc.

    SC 13G/A - AGILENT TECHNOLOGIES, INC. (0001090872) (Subject)

    11/12/24 1:27:37 PM ET
    $A
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    SEC Form SC 13G filed by Agilent Technologies Inc.

    SC 13G - AGILENT TECHNOLOGIES, INC. (0001090872) (Subject)

    11/12/24 11:54:03 AM ET
    $A
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    SEC Form SC 13G filed by Agilent Technologies Inc.

    SC 13G - AGILENT TECHNOLOGIES, INC. (0001090872) (Subject)

    11/4/24 10:57:57 AM ET
    $A
    Biotechnology: Laboratory Analytical Instruments
    Industrials